Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).

The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.   

Please refer to the full announcement as attached.

This announcement is dated 23 November 2020.